A detailed history of Allianz Asset Management Gmb H transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Allianz Asset Management Gmb H holds 21,673 shares of NBIX stock, worth $2.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,673
Previous 27,468 21.1%
Holding current value
$2.51 Million
Previous $3.79 Million 21.25%
% of portfolio
0.0%
Previous 0.01%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$130.86 - $143.19 $758,333 - $829,786
-5,795 Reduced 21.1%
21,673 $2.98 Million
Q1 2024

May 13, 2024

SELL
$130.4 - $143.74 $279,056 - $307,603
-2,140 Reduced 7.23%
27,468 $3.79 Million
Q4 2023

Feb 12, 2024

SELL
$106.07 - $132.76 $5.57 Million - $6.97 Million
-52,518 Reduced 63.95%
29,608 $3.9 Million
Q3 2023

Nov 13, 2023

SELL
$94.02 - $117.1 $164,158 - $204,456
-1,746 Reduced 2.08%
82,126 $9.24 Million
Q2 2023

Aug 11, 2023

SELL
$89.53 - $104.87 $14.1 Million - $16.5 Million
-157,121 Reduced 65.2%
83,872 $7.91 Million
Q1 2023

May 11, 2023

SELL
$94.11 - $123.02 $935,076 - $1.22 Million
-9,936 Reduced 3.96%
240,993 $24.4 Million
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $7.86 Million - $9.35 Million
73,619 Added 41.52%
250,929 $30 Million
Q3 2022

Nov 08, 2022

SELL
$92.03 - $107.81 $6.29 Million - $7.37 Million
-68,354 Reduced 27.82%
177,310 $18.8 Million
Q2 2022

Aug 12, 2022

SELL
$75.79 - $100.07 $1.54 Million - $2.04 Million
-20,358 Reduced 7.65%
245,664 $23.9 Million
Q1 2022

May 13, 2022

BUY
$72.45 - $94.81 $4.87 Million - $6.38 Million
67,248 Added 33.83%
266,022 $24.9 Million
Q4 2021

Feb 11, 2022

SELL
$79.65 - $106.22 $1.8 Million - $2.41 Million
-22,653 Reduced 10.23%
198,774 $16.9 Million
Q3 2021

Nov 10, 2021

BUY
$86.18 - $99.03 $5.07 Million - $5.83 Million
58,850 Added 36.2%
221,427 $21.2 Million
Q2 2021

Aug 16, 2021

BUY
$89.43 - $102.27 $7.52 Million - $8.6 Million
84,096 Added 107.15%
162,577 $15.8 Million
Q1 2021

May 13, 2021

BUY
$87.57 - $119.4 $79,338 - $108,176
906 Added 1.17%
78,481 $7.63 Million
Q4 2020

Feb 16, 2021

BUY
$86.91 - $108.33 $2.33 Million - $2.91 Million
26,844 Added 52.91%
77,575 $7.44 Million
Q3 2020

Nov 13, 2020

BUY
$96.16 - $135.15 $966,023 - $1.36 Million
10,046 Added 24.69%
50,731 $4.88 Million
Q2 2020

Aug 14, 2020

SELL
$85.09 - $130.36 $269,905 - $413,501
-3,172 Reduced 7.23%
40,685 $4.96 Million
Q1 2020

May 14, 2020

SELL
$75.11 - $113.76 $919,271 - $1.39 Million
-12,239 Reduced 21.82%
43,857 $3.8 Million
Q4 2019

Feb 13, 2020

SELL
$86.8 - $118.57 $4.96 Million - $6.77 Million
-57,135 Reduced 50.46%
56,096 $6.03 Million
Q3 2019

Nov 13, 2019

SELL
$83.82 - $101.5 $3.74 Million - $4.53 Million
-44,625 Reduced 28.27%
113,231 $10.2 Million
Q2 2019

Aug 08, 2019

SELL
$72.24 - $91.27 $487,547 - $615,981
-6,749 Reduced 4.1%
157,856 $13.3 Million
Q1 2019

May 13, 2019

SELL
$69.31 - $91.53 $8.44 Million - $11.1 Million
-121,765 Reduced 42.52%
164,605 $14.5 Million
Q4 2018

Feb 14, 2019

SELL
$68.32 - $124.36 $5.57 Million - $10.1 Million
-81,536 Reduced 22.16%
286,370 $20.4 Million
Q3 2018

Nov 13, 2018

SELL
$98.88 - $125.85 $164,437 - $209,288
-1,663 Reduced 0.45%
367,906 $45.2 Million
Q2 2018

Aug 13, 2018

SELL
$75.3 - $105.99 $2 Million - $2.81 Million
-26,531 Reduced 6.7%
369,569 $36.3 Million
Q1 2018

May 14, 2018

BUY
$75.88 - $92.43 $3.47 Million - $4.23 Million
45,775 Added 13.07%
396,100 $32.8 Million
Q4 2017

Feb 13, 2018

BUY
$58.53 - $77.59 $18.2 Million - $24.1 Million
310,214 Added 773.39%
350,325 $27.2 Million
Q3 2017

Nov 13, 2017

BUY
$47.97 - $61.28 $3,597 - $4,596
75 Added 0.19%
40,111 $2.46 Million
Q2 2017

Aug 14, 2017

SELL
N/A
-184,833 Reduced 82.2%
40,036 $1.85 Million
Q4 2016

Apr 17, 2019

SELL
N/A
-3,876 Reduced 1.69%
224,869 $8.7 Million
Q3 2016

Apr 17, 2019

BUY
N/A
228,745
228,745 $11.5 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.